MN-VÄRDE-PARTNERS
14.1.2021 14:02:39 CET | Business Wire | Press release
Värde Partners, a leading global alternative investment firm, is pleased to announce that Brendan Albee has been promoted to Partner.
“Over the past six years, Brendan has demonstrated strong leadership and character while driving advances in scaling our world-class global operations and infrastructure. His direction and forethought have proven instrumental to the growth and success of the firm in many ways, not least of which includes ensuring Värde was well prepared with the technology and systems for a seamless transition to remote work in 2020. We are excited to welcome him as a partner,” said George Hicks, Värde Co-Founder and Co-CEO, and Ilfryn Carstairs, Co-CEO and CIO.
Brendan joined Värde in 2014 to serve as the firm’s Chief Operating Officer with global responsibility for the accounting, treasury, valuations, operations and technology functions. Based in Minneapolis, he is a member of the firm’s Investment Committee, Senior Leadership Committee, and Operating Committee. He is also active in the firm’s fund and product development as well as enterprise risk management.
Prior to joining Värde, Brendan served as global COO for the Alternative Asset Management, Equities, Structured Products, Asset Servicing and Securities Operations teams at Barclays Bank. Prior to Barclays, Brendan spent more than a decade in various roles within audit, investment banking, and strategy at JPMorgan Chase.
Alongside Brendan’s appointment, Värde announced two promotions to Senior Managing Director:
- Ria Nova, Head of Americas Business Development and Investor Relations, also oversees the firm’s consultant, intermediary and product specialist efforts. Based in New York, she joined the firm in 2017.
- Michael Reimler, Global Head of Finance, is responsible for leading and managing the accounting and financial reporting for Vӓrde’s investment funds, general partner entities and management companies, and for leading and managing the firm’s Treasury function. Based in Minneapolis, he joined the firm in 2010.
In addition, Värde recently hired Monty Cook as Head of Financial Services, North America. Based in New York, Monty leads the firm’s investing in financial services assets across North America with a focus on private credit investments in traditional and emerging asset classes. He reports to Aneek Mamik, Global Co-Head of Financial Services.
“We’re pleased to welcome Monty at an exciting time for the financial services team,” said Aneek. “Leveraging Monty’s tremendous industry experience and the strength of Värde’s platform, we are pleased to be expanding our lending solutions for the financial services sector and building on the firm’s capabilities to deliver value for investors.”
Monty joins Värde from First Eagle Alternative Credit, where he served as Head of Financial Services. Monty was with THL Credit for seven years before it was acquired by First Eagle and most recently served as Co-Head of Direct Lending. Prior to THL Credit, Monty was a Director in Deutsche Bank’s Credit Solutions Group where he sourced and structured credit investments across numerous specialty finance and other asset classes.
About Värde Partners:
Värde Partners is a leading global alternative investment firm with roots in credit and distressed. Founded in 1993, the firm has invested more than $75 billion since inception and manages over $14 billion on behalf of a global investor base. The firm’s investments span corporate and traded credit, real estate and mortgages, private equity and direct lending. Värde employs more than 300 professionals worldwide with offices in Minneapolis, New York, London, Singapore and other cities in Asia and Europe. For more information, please visit www.varde.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005214/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
